Increased Risk of Myositis Autoantibodies After COVID-19 Vaccination
Author Information
Author(s): García-Bravo Laura, Prada Alvaro, Gutiérrez Larrañaga María, Espinosa Ros Eduardo, Almeida González Delia, Martín Martínez Dolores, Rodríguez Sánchez Telesforo, Mingorance Gámez Carlos Gustavo, Jurado Roger Aurora, Aguado Álvarez Rocío, Díaz Luna María De Las Mercedes, Rodríguez Hernández Carmen, de la Varga-Martínez Raquel, López-Cueto María, Julià Benique Maria Rosa, San José-Cascón Miriam, Quirant-Sánchez Bibiana, Martínez-Chamorro Alba, Marcaida-Benito Goitzane, Timoneda Timoneda Pilar Teresa, Fandos Sánchez Marta, Sacristán Enciso Beatriz, Mohamed Mohamed Kauzar, Guerra-Galán Teresa, Villegas Ángela, Roncancio-Clavijo Andrés, Rodríguez-Mahou Margarita, Sánchez-Ramón Silvia, Fernández-Arquero Miguel, Candelas-Rodríguez Gloria, Ochoa-Grullón Juliana
Primary Institution: Hospital Clínico San Carlos, Madrid, Spain
Hypothesis
This study aimed to describe the incidence of idiopathic inflammatory myopathies (IIM) following SARS-CoV-2 infection or vaccination and compare rates between exposures.
Conclusion
The study found distinct patterns of myositis autoantibodies associated with SARS-CoV-2 infection and vaccination, indicating increased autoimmune risks.
Supporting Evidence
- 91.13% of patients received at least one dose of an mRNA COVID-19 vaccine.
- Anti-PL-7 was the most prevalent autoantibody detected at 14.85%.
- ANA positivity was observed in 60.66% of patients, indicating an autoimmune background.
- Patients with prior SARS-CoV-2 infection showed a higher frequency of multiple autoantibody positivity.
Takeaway
This study shows that some people may develop autoimmune responses, like myositis, after getting COVID-19 or the vaccine.
Methodology
A multicenter observational study analyzed 788 patients from 11 Spanish referral centers for myositis autoantibodies using line blot immunoassay.
Potential Biases
Potential biases due to the retrospective design and exclusion of patients with concomitant infections unrelated to SARS-CoV-2.
Limitations
The study lacked uniformity in diagnostic criteria and cutoff points for positivity across different centers.
Participant Demographics
The median age of participants was 61 years, with a female predominance (66.37%).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website